Good evening :)
$
₹
V

Veraxa Biotech AG Warrants

VRXAW

US
V

Veraxa Biotech AG Warrants

VRXAW

US
$0.0718.58% (-0.01)
$
₹
$0.0718.58% (-0.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Unknown

Sector and industry information not available

Unknown

Recent listing (market-cap unavailable as on date)

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

—
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company utilizes proprietary payloads and genetic code expansion technology to engineer and manufacture homogeneous, stable bioconjugates with defined drug-to-antibody ratios. It also licenses technology platforms to support the development of new therapeutic strategies. The company serves professional clients in the healthcare sector, including those in drug development, biologicals, diagnostics, instrumentation, and partners with research organizations and business partners in the life sciences industry. The company was founded in 2021 and is based in Heidelberg, Germany.

Peers

Peers

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Financials

Financials

Income

Balance Sheet

Cash Flow

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Frequently asked questions

Frequently asked questions

  1. Veraxa Biotech AG Warrants (VRXAW) share price today is $0.07 as of September 10, 2026 at 8:21 PM IST. The stock touched a day high of $0.00 and a day low of $0.00.

  2. Veraxa Biotech AG Warrants stock trades on US under the ticker symbol VRXAW.

  3. Veraxa Biotech AG Warrants's market capitalization is N/A as of September 10, 2026 at 8:21 PM IST.

  4. Veraxa Biotech AG Warrants's price-to-earnings (P/E) ratio is N/A as of September 11, 2026.

  5. Veraxa Biotech AG Warrants's price-to-book (P/B) ratio is 0 as of September 11, 2026.

  6. Yes, You can buy Veraxa Biotech AG Warrants shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Veraxa Biotech AG Warrants shares in three steps: 1. Search Veraxa Biotech AG Warrants on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Veraxa Biotech AG Warrants trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Veraxa Biotech AG Warrants (VRXAW) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 126.1034 shares at the current price of $0.07.

Loading...